Israeli, Portuguese researchers develop COVID-19 nasal spray vaccine

A collaborative team from Tel Aviv University and the University of Lisbon, led by Ronit Satchi-Fainaro and Helena Florindo, has created an innovative COVID-19 vaccine administered via nasal spray.

This vaccine is notable for its stability, as it can be stored at room temperature, eliminating the need for refrigeration or special handling. Additionally, its simple administration process, which does not require trained medical professionals, minimizes the risk of contamination and medical waste, Caliber.Az reports citing foreign media.

The vaccine offers significant potential in addressing vaccination challenges, especially in remote and low-income areas where infrastructure may be limited.

Satchi-Fainaro explained that the vaccine is based on nanoparticles and developed using two specific amino acid sequences found in the virus’s protein. These sequences are encapsulated in a nano-vaccine that can be administered without the need for needles.

She also emphasized the ease of production, stating, “The vaccine is created by simply mixing the powder with a saline solution to form the spray.”

Initial trials have shown the vaccine's efficacy against major COVID-19 variants, including Beta, Delta, and Omicron. This development could greatly simplify the global vaccination effort and provide a more accessible option for underserved populations.

By Vafa Guliyeva